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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S1626.4±2.7 mg/m2/day. ATRA syndrome was observed in 10/34 (29.4%) and
was non-fatal. Prophylactic dexamethasone was used in 14 (73.7%) out of
19 high-risk patients. Sixteen (39%) patients died; of which 15 (94%) died
within 15-days of diagnosis. The cause of death included, intracranial
bleed (82%) and septicemia (18%). There was merely onemortality beyond
induction from febrile neutropenia following ﬁrst cycle of consolidation.
The risk category did not predict mortality (p¼0.52). There was no cor-
relation of <15 day mortality with platelet count (p¼0.61) or coagulop-
athy (p¼0.12). No patient died or abandoned treatment following 2-
months of treatment. The median follow-up of patients who continued
treatment beyond 2 months was 22 months (range: 1.5-141). No patient
relapsed. The 10-year OS as well as EFS of the cohort (n¼41) was 58.4±8%
and for patients who survived 15 days from diagnosis (n¼26) OS/EFS
was 95.2±4.6% (p¼0.01).
Conclusion: The EFS of all children with APML, and of those who survived
15 days from diagnosis was 58.4±8% and 95.2±4.6%, respectively (ﬁgure
1). Early (<15 days from diagnosis) mortality is predominantly caused by
intracranial hemorrhage and is a major impediment to survival in children
with APML.Figure 1. Comparison of survival between entire cohort and those excluding early
mortality.MM-1_V1.5
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Abstract
Introduction: Therapy related acute myeloid leukaemia (t-AML) is a rare,
though devastating late effect of cancer treatment. Alkylating agents, DNA
topoisomerase II inhibitors and radiotherapy have been mainly implicated
as causative agents. Usually these are refractory to antileukemic therapy
and warrants allogenic bone marrow transplant.
Material andMethods: This is a retrospective analysis of patients less than
18 years of age treated in paediatric Hematology-Oncolgy unit at our
institute between January 1996 and December 2015. Amongst these, pa-
tients who developed t-AML were identiﬁed. Information pertaining to
primary malignancy and its treatment along with clinical, hematologic,
cytogenetic features and outcome of t- AML were collected.Results: Amongst 1543 children treated during this period, eight patients
developed t-AML (6 males and 2 females) with a median age of 15.5 years
(range, 4-22 years). Overall incidence of t-AML was 0.5% [0.7% (4/515) in
solid tumours compared to 0.4% (4/1028) in leukemia/lymphoma, P¼0.45]
with a median follow up of 7 years. Primary malignancy included sarcoma
in 4 patients (one each with osteosarcoma, rhabdomyosarcoma Ewings
and synovial sarcoma) and hematolymphoid malignancy in 4 patients
[two each with B-non-Hodgkin lymphoma (NHL) and acute lymphoblastic
leukemia (ALL)]. Presenting features of t-AML were non resolving fever (6/
8), bone pains (3/8), gingival hyperplasia (5/8) and bleeding manifestation
(4/8) with a median latency period of 24 months (range 16.5-62 months).
Only 1/8 patients had a preleukemic phase. The FAB morphology was M2
(1/8) and M4/M5 (7/8). Of 6 patients whom cytogenetic studies were
available, 4 had MLL rearrangement. Total cumulative cyclophosphamide
equivalent dose was 28.3 g/m2, 27.7 g/m2 and 13.1g/m2 in patients with
Ewings sarcoma, rhabdomyosarcoma and synovial sarcoma respectively
and 3 g/m2, 6.8 g/m2 in patients with ALL and B-NHL (group C). The cu-
mulative dose of etoposide was 4 g/m2 in patients with Ewings sarcoma
and rhabdomyosarcoma, 1g/m2 in synovial sarcoma and 2.5 g/m2 in B-NHL
(group C). The median cumulative dose of anthracyclin was 367mg/m2
(range, 300- 375mg/m2) in sarcoma patients and 240mg/m2 (range, 180-
240mg/m2) in leukemia/lymohoma patients. Two patients received
radiotherapy to primary site [1 RMS (50Gy), 1 Synovial sarcoma (45Gy)].
Treatment for t-AML was opted by 5/8 patients out of which three ach-
ieved complete remission and one is currently on induction. Three patients
died [2 toxic death (1 during induction, 1 during remission) and 1 relapse/
progressive disease]. One patient (post allogenic BMT) is alive and disease
free at 25 months of follow up.
Conclusions: We observed a high incidence of t-AML in children with
pediatric sarcoma compared to haematological malignancies. Shorter la-
tency period, absence of preleukemic phase, presence of MLL gene im-
plicates epipodophyllotoxin to be the probable causative agent. In view of
poor outcome with conventional therapy, novel strategies need to be
considered.
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Abstract
Background: Juvenile myelomonocyticleukemia (JMML) is a potentially
fatal, rare clonal haematopoietic myeloprolifertive/ myelodysplastic group
of disorders of childhood characterized by excessive proliferation of the
granulocytic and monocytic lineages. JMML is known to mimic/co-exist
with viral infections which further makes the diagnosis difﬁcult and
delayed. The aim of this study is to highlight the high incidence of JMML
coexisting with viral infections, in particular herpes group of viruses in
Indian scenario leading to diagnostic dilemma and subsequent delay in
management.
Material and methods: Retrospective analysis of case records of eleven
patients diagnosed with was done. The diagnosis was established based on
International JMML working group diagnostic criteria.
Results: JMML constituted 3% of all haematological malignancies and 1% of
all childhood malignancies reporting to our centre. Three of the eleven
childrenwith JMML presentedwith co-existing Cytomegalo virus infection
while two had co-existing EBV infection. All three patients of JMML with
co-existing CMV infection died early due to disease progression while
those with co-existing EBV and EBV and parvo virus B19 infection are alive
after 24 months and 8 months of disease presentation.
Conclusion: JMML with co-existing CMV infections leads to poor outcome
and it must be considered as a differential diagnosis in children as it
mimics /co-exists with viral infection.
Our study is ﬁrst case series on JMML with coexisting viral infections from
Indian subcontinent.
